What do systematic reviews say?

Platinum‐containing chemotherapy vs chemotherapy without platinum

Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).

• Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
  HR 0.7 [0.5, 0.96]
  4 studies · 1256 participants
  High

Platinum‐containing chemotherapy vs chemotherapy without platinum

Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).

• Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
  HR 0.7 [0.5, 0.96]
  4 studies · 1256 participants
  High

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1250 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.37, 3.17]
  1 study · 137 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.16 [0.01, 2.99]
  1 study · 147 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.82 [0.63, 1.06]
  2 studies · 240 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1099 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 295 participants
  Very low

Intervention not reported

The intervention may leads to lower general health‐related quality of life [assessed using a variety of… (low certainty).

• Specialist breast care nurses for support of women with breast cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1328 participants
  Low

Intervention not reported

• Specialist breast care nurses for support of women with breast cancer 2021 · Cochrane Headline outcomes only
  2009
  2 studies · 557 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in anxiety and depression [HADS, STAI, (moderate certainty).

• Specialist breast care nurses for support of women with breast cancer 2021 · Cochrane Headline outcomes only
  RR 1.8 [0.4, 7.2]
  3 studies · 1094 participants
  Moderate

Intervention not reported

The intervention probably leads to lower service provision‐ patient perspective [ (moderate certainty).

• Specialist breast care nurses for support of women with breast cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1331 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Specialist breast care nurses for support of women with breast cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found